ArticleCancer medicine2019
The establishment of immune infiltration based novel recurrence predicting nomogram in prostate cancer.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 43 citations in OpenAlex.
- Decoding the metabolic‑immune crosstalk: The role of glutamine and ammonium reprogramming in prostate cancer immune evasion (Review).Oncology reports · 2026Review
- Unveiling oncogene-induced senescence: a new frontier in prostate cancer prognosis and therapy.Discover oncology · 2025Article
- Telomerase related molecular subtype and risk model reveal immune activity and evaluate prognosis and immunotherapy response in prostate cancer.Cancer cell international · 2024Article
- Identifying the tumor immune microenvironment-associated prognostic genes for prostate cancer.Discover oncology · 2024Article
- Construction of a novel nomogram based on competing endogenous RNAs and tumor-infiltrating immune cells for prognosis prediction in elderly patients with colorectal cancer.Discover oncology · 2023Article
- Correlation analysis between immune-related genes and cell infiltration revealed prostate cancer immunotherapy biomarkers linked to T cells gamma delta.Scientific reports · 2023Article
- High infiltration of CD209Frontiers in immunology · 2023Article
- Elevated expression of TNFRSF4 impacts immune cell infiltration and gene mutation in hepatocellular carcinoma.Cancer biomarkers : section A of Disease markers · 2023Article
- TMEM147 is a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma.Genetics and molecular biology · 2023Article
- Nomogram for predicting the overall survival of patients with early-onset prostate cancer: A population-based retrospective study.Cancer medicine · 2022Article
- Risk subtyping and prognostic assessment of prostate cancer based on consensus genes.Communications biology · 2022Article
- Development and external validation of a nomogram for predicting renal function based on preoperative data from in-hospital patients with simple renal cysts.The Journal of international medical research · 2022Article
- Macrophages and monocytes mediated activation of oxidative phosphorylation implicated the prognosis and clinical therapeutic strategy of Wilms tumour.Computational and structural biotechnology journal · 2022Article
- CD146 is closely associated with the prognosis and molecular features of osteosarcoma: Guidance for personalized clinical treatment.Frontiers in genetics · 2022Article
- Article
- Early B-cell factors involve in the tumorigenesis and predict the overall survival of gastric cancer.Bioscience reports · 2021Article
- Immune response drives outcomes in prostate cancer: implications for immunotherapy.Molecular oncology · 2021Article
- Comprehensive Analysis of the Relationship Between Metabolic Reprogramming and Immune Function in Prostate Cancer.OncoTargets and therapy · 2021Article
- miR-182 modulates cell proliferation and invasion in prostate cancer via targeting ST6GALNAC5.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Article
- Extracellular Vesicles fromInternational journal of nanomedicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Prostate cancer (PCa), a severe health burden for males, accounts for the second frequent cancer and fifth tumor specific death cancer around the world. Several studies on tumor-infiltrating immune cells (TIICs) have shown inconsistent and controversial results to PCa. We downloaded a gene expression matrix and clinical information from TCGA, and CIBERSORT was used to identify the proportion of TIICs. Wilcoxon's Sign Rank Test evaluated different gene expression levels in PCa and normal tissues. Kaplan-Meier curves were used to evaluate the associations of TIICs and recurrence-free survival (RFS). Finally, based on the preset P-value of .05, the distribution of TIICs in 73 PCa tissues and 11 normal tissues was illustrated. Activated CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.